We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

38 hedge funds and large institutions have $118M invested in Marinus Pharmaceuticals, Inc in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,050% more capital invested

Capital invested by funds: $10.3M → $118M (+$108M)

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

156% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 9

58% more funds holding

Funds holding: 24 → 38 (+14)

Holders
38
Holders Change
+14
Holders Change %
+58.33%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
23
Increased
9
Reduced
2
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$10.2M
2
GPCM
Granite Point Capital Management
Massachusetts
+$5.38M
3
PA
Perceptive Advisors
New York
+$4.07M
4
DM
Deerfield Management
New York
+$3.8M
5
FCM
Farallon Capital Management
California
+$3.28M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.82M
2
JGC
J. Goldman & Co
New York
-$940K
3
ARTA
A.R.T. Advisors
New York
-$66K
4
BFM
Boothbay Fund Management
New York
-$43K
5
TRCT
Tower Research Capital (TRC)
New York
-$14.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$268K +$67.8K +6,052 +113%
EMG
27
Ellington Management Group
Connecticut
$265K +$126K +11,275 New
State Street
28
State Street
Massachusetts
$235K +$112K +10,025 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$128K +$61.2K +5,461 New
CC
30
Caxton Corporation
New Jersey
$95K +$45.4K +4,050 New
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$89K +$42.3K +3,775 New
ACH
32
ArrowMark Colorado Holdings
Colorado
$70K +$33.7K +3,002 New
VF
33
Virtu Financial
New York
$66K +$31.7K +2,824 New
SAMH
34
Shanda Asset Management Holdings
British Virgin Islands
$59K – – –
CBT
35
Capital Bank & Trust
California
$24K – – –
Simplex Trading
36
Simplex Trading
Illinois
$5K +$2.71K +242 New
Morgan Stanley
37
Morgan Stanley
New York
$2K -$605 -54 -44%
Deutsche Bank
38
Deutsche Bank
Germany
$1K +$112 +10 +25%
SFM
39
Sphera Funds Management
Israel
– -$1.82M -332,855 Closed
ARTA
40
A.R.T. Advisors
New York
– -$66K -12,165 Closed
BFM
41
Boothbay Fund Management
New York
– -$43K -7,866 Closed
TRCT
42
Tower Research Capital (TRC)
New York
– -$14.6K -1,300 Closed
Acadian Asset Management
43
Acadian Asset Management
Massachusetts
– -$6K -1,082 Closed
PAM
44
Panagora Asset Management
Massachusetts
– -$5K -893 Closed
UBS Group
45
UBS Group
Switzerland
– -$4K -654 Closed
Creative Planning
46
Creative Planning
Kansas
– -$1K -125 Closed
1
2

MRNS Hedge Fund Activity: Q3 2017 in Review

38 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2017, worth a combined $118M — up 1,050% from $10.3M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new MRNS positions and 9 closed out — a net gain of 14 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $10.2M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.82M sold.

  • 38 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2017, up from 24 in Q2 2017.
  • Funds reported $118M of Marinus Pharmaceuticals, Inc stock for Q3 2017, up 1,050% quarter-over-quarter.
  • 23 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2017 and 9 closed out, a net change of +14 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q3 2017 was EcoR1 Capital, an estimated $10.2M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q3 2017 was Sphera Funds Management, an estimated $1.82M sold.

Based on aggregated 13F filings for Q3 2017.